Medline (Nasdaq: MDLN) priced an upsized secondary offering of 72,554,594 Class A shares by selling stockholders at $37.00 per share. Underwriters have a 30-day option for up to 10,883,189 additional shares. The offering should close on May 28, 2026, and Medline will not receive proceeds.
Loading…
Loading translation…
AI-generated analysis. Not financial advice.
Positive
- No dilution to existing shareholders, as Medline is not issuing or selling any shares
- Large, underwritten secondary offering may broaden MDLN’s public float and trading volume
Negative
- Medline will not receive any of the cash proceeds from this secondary offering
- Significant block of 72,554,594 shares is being sold by existing large shareholders
Offering size
72,554,594 shares
Upsized secondary offering by selling stockholders
Offering price
$37.00 per share
Public offering price for Class A common stock
Underwriters’ option
10,883,189 shares
30-day option to purchase additional shares
Option period
30 days
Underwriters’ additional share purchase option duration
Expected close date
May 28, 2026
Anticipated closing of the secondary offering
$37.01
Last Close
Volume
Volume 16,368,176 is 2.12x the 20-day average of 7,703,745, indicating elevated trading interest ahead of this secondary sale.
high
Technical
Shares at $37.10 are trading below the 200-day MA of $43.66 and about 27.08% under the 52-week high, modestly above the 52-week low.
No peers from the Medical Instruments & Supplies group appeared in the momentum scanner, suggesting MDLN’s 2.34% move and heavy volume are stock-specific to this secondary offering.
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| May 20 |
Secondary launch |
Negative |
-3.4% |
Launch of 60M-share secondary by selling stockholders with 9M-share option. |
| Mar 10 |
Secondary closing |
Negative |
-1.2% |
Closing of 86.25M-share secondary and full exercise of 11.25M-share option. |
| Mar 04 |
Secondary pricing |
Negative |
+2.7% |
Pricing of 75M-share secondary at $41.00 with 11.25M-share option. |
| Mar 03 |
Secondary launch |
Negative |
-3.2% |
Launch of 75M-share underwritten offering by private equity sponsors. |
Offering-related headlines for MDLN have typically seen mildly negative reactions, with an average move of about -1.27% and 3 of 4 past events trading in the same (negative) direction as the perceived overhang risk.
Over recent months, Medline has repeatedly used underwritten secondary offerings for existing holders, with Blackstone, Carlyle, Hellman & Friedman and ADIA selling large Class A blocks. Past offering and pricing announcements between Mar 3–10, 2026 involved transactions from 75,000,000 to 86,250,000 shares, usually with Medline receiving no proceeds. Those events generally produced modestly negative single‑day moves, framing today’s upsized pricing as part of an ongoing sponsor sell‑down.
-1.3%
Average Historical Move
offering
In the past four offering-related headlines, MDLN moved an average of -1.27%, mostly mildly negative. Today’s pricing news with a 2.34% gain contrasts with that pattern.
Recent activity shows a sequence of sponsor-led secondary offerings, from launch to pricing to closing, steadily transferring large Class A blocks from private equity and institutional holders into the public float without Medline receiving proceeds.
This announcement prices an upsized secondary of 72,554,594 Class A shares at $37.00, with a 30‑day option for 10,883,189 more, all sold by existing holders while Medline receives no proceeds. Similar offering headlines over recent months averaged a -1.27% move, underscoring how repeated sponsor sell‑downs can shape sentiment. Investors may watch future transaction sizes and pacing of these secondary sales.
secondary offering
financial
“announces pricing of its upsized secondary offering of 72,554,594 shares”
A secondary offering is when a company sells new shares of its stock to the public after its initial sale. This allows existing shareholders or the company itself to raise additional money. For investors, it can impact the stock’s price by increasing the total number of shares available, which may influence the stock’s value and how the market perceives the company’s financial health.
class a common stock
financial
“offering of 72,554,594 shares of Medline Inc.’s Class A common stock”
Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.
underwriters
financial
“The Selling Stockholders have also granted the underwriters a 30-day option”
Underwriters are financial professionals or institutions that help companies raise money by selling new securities, such as stocks or bonds, to investors. They assess the risk and determine the price at which these securities should be sold, acting like a bridge between the company and the investors. Their role helps ensure that the company raises the needed funds while providing investors with options that reflect the level of risk involved.
prospectus
regulatory
“The offering of these securities is being made only by means of a prospectus.”
A prospectus is a detailed document that explains a company’s plans for offering new shares or investments to the public. It’s important because it provides potential investors with key information about the company’s business, risks, and how they might make money, helping them decide whether to invest. Think of it as a guidebook for understanding what you’re buying into.
registration statement
regulatory
“A registration statement relating to these securities was filed with, and declared”
A registration statement is a formal document that companies file with a government agency to offer new shares of stock to the public. It provides essential information about the company’s finances, operations, and risks, helping investors make informed decisions. Think of it as a detailed product description that ensures transparency and trust before buying into a company.
securities and exchange commission
regulatory
“declared effective by, the Securities and Exchange Commission (the “SEC”).”
A national government agency that enforces rules for buying, selling and disclosing information about stocks and other investments, acting like a referee and scorekeeper for financial markets. It requires companies to share clear, regular financial and business information and investigates fraud or rule-breaking, which matters to investors because those rules and disclosures help ensure fair prices, reduce hidden risks and make it easier to compare investment choices.
AI-generated analysis. Not financial advice.
NORTHFIELD, Ill., May 21, 2026 (GLOBE NEWSWIRE) — Medline Inc. (Nasdaq: MDLN) (“Medline”) announced today the pricing of its upsized secondary offering of 72,554,594 shares of Medline Inc.’s Class A common stock by certain selling stockholders affiliated with Blackstone Inc., Hellman & Friedman LLC and a wholly owned subsidiary of the Abu Dhabi Investment Authority (the “Selling Stockholders”) at a price to the public of
Medline is not selling any shares of Class A common stock in the offering and will not receive any of the proceeds from the sale.
Goldman Sachs & Co. LLC, Morgan Stanley, BofA Securities and J.P. Morgan are acting as global coordinators and joint bookrunning managers. Barclays, Citigroup, Deutsche Bank Securities, Jefferies, UBS Investment Bank, Evercore ISI, BMO Capital Markets, BNP Paribas, MUFG, RBC Capital Markets, Santander, Societe Generale, TD Cowen, Wells Fargo Securities, Wolfe | Nomura Alliance, Leerink Partners, Macquarie Capital, Mizuho, Piper Sandler, Truist Securities and William Blair are acting as bookrunning managers, and Blackstone Capital Markets, Carlyle, Baird, Rothschild & Co, Stifel, BTIG, ING, IMI – Intesa Sanpaolo, NCMG, Perella Weinberg, Academy Securities, AmeriVet Securities, Blaylock Van, LLC, C.L. King & Associates, Drexel Hamilton, Loop Capital Markets, Mischler Financial Group, Inc., R. Seelaus & Co., LLC, Ramirez & Co., Inc., Siebert Williams Shank and Tigress Financial Partners are acting as co-managers for the offering.
The offering of these securities is being made only by means of a prospectus. When available, copies of the prospectus relating to this offering may be obtained from: Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, by telephone at 1-866-471-2526, or by email at prospectus-ny@ny.email.gs.com; Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014 or by email at prospectus@morganstanley.com; BofA Securities, Attention: Prospectus Department, NC1-022-02-25, 201 North Tryon Street, Charlotte, North Carolina 28255-0001 or by email at dg.prospectus_requests@bofa.com; and J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717 or by email at prospectus-eq_fi@jpmchase.com and postsalemanualrequests@broadridge.com.
A registration statement relating to these securities was filed with, and declared effective by, the Securities and Exchange Commission (the “SEC”). This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Medline
Medline is the largest provider of medical-surgical products and supply chain solutions serving all points of care. Through its broad product portfolio, resilient supply chain and leading clinical solutions, Medline helps healthcare providers improve their clinical, financial and operational outcomes. Headquartered in Northfield, Ill., the company employs more than 45,000 people worldwide and operates in more than 100 countries.
Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. Words such as “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “foreseeable,” “intend,” “may,” “plan,” “potentially,” “predict,” “project,” “seek,” “should,” “will,” or “would,” or similar conditional or future expressions, are intended to identify forward-looking statements. Examples of forward-looking statements include, but are not limited to, statements related to Medline’s industry, business strategy, costs, and cost savings, goals and expectations, market position, future operations, margins, profitability, annual guidance, and other financial and operating information. The forward-looking statements are based on management’s current expectations and are subject to various risks, uncertainties, and changes in circumstances, many of which are beyond Medline’s control, that could cause actual results to differ materially.
Although we believe that the assumptions underlying the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance or achievements. Accordingly, there are or will be important factors that may cause actual results to differ from expected results. These factors include but are not limited to those described under “Risk Factors” in Medline’s registration statement on Form S-1, as amended, relating to the offering and “Item 1A. Risk Factors” in Medline’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, as filed with the SEC, as such factors may be updated from time to time in Medline’s periodic filings with the SEC. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in Medline’s filings with the SEC. Except as otherwise required by law, we disclaim any intent or obligation to update any “forward-looking statement” made in this press release to reflect changed assumptions, the occurrence of unanticipated events, or changes to future operating results over time.
Contacts:
Investor Relations:
Karen King
Global Head Investor Relations
Patrick Flaherty
Director, Investor Relations
(847) 247-7222
IR@medline.com
Media Relations:
Ben Fox
Vice President, Corporate Communications
(224) 327-9999
media@medline.com
Source: Medline Inc.
FAQ
What did Medline (Nasdaq: MDLN) announce about its May 2026 secondary offering pricing?
Medline announced an upsized secondary offering priced at $37.00 per share. According to Medline, 72,554,594 Class A shares will be sold by existing stockholders, with underwriters holding a 30-day option for up to 10,883,189 additional shares.
Will Medline (MDLN) receive proceeds from the May 2026 secondary stock offering?
Medline will not receive any proceeds from this secondary offering. According to Medline, all shares are being sold by stockholders affiliated with Blackstone, Hellman & Friedman and Abu Dhabi Investment Authority, so the company’s balance sheet will remain unchanged by this transaction.
When is the Medline (MDLN) upsized secondary offering expected to close?
The secondary offering is expected to close on May 28, 2026. According to Medline, completion is subject to customary closing conditions, meaning timing could shift slightly if standard documentation, regulatory, or settlement requirements are not satisfied as anticipated.
Who are the selling stockholders in the Medline (MDLN) May 2026 secondary offering?
The selling stockholders are affiliates of Blackstone, Hellman & Friedman and a subsidiary of the Abu Dhabi Investment Authority. According to Medline, these investors, not the company, are offering the 72,554,594 Class A shares to the public.
Which banks are leading the Medline (MDLN) May 2026 secondary stock offering?
Goldman Sachs, Morgan Stanley, BofA Securities and J.P. Morgan are global coordinators and joint bookrunners. According to Medline, numerous additional banks act as bookrunning managers and co-managers, reflecting broad underwriting support for this secondary stock offering.
Is the Medline (MDLN) May 2026 secondary offering made under an effective SEC registration?
Yes, the secondary offering is being made under an effective SEC registration statement. According to Medline, the registration relating to these securities was filed with and declared effective by the Securities and Exchange Commission before the shares were offered to investors.